NCT02646839 KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT Children Status ENROLLING_BY_INVITATION Phase PHASE2
NCT02641002 A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS) Status TERMINATED Phase PHASE1
NCT02631070 A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes Status COMPLETED Phase PHASE3
NCT02627573 Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT Status TERMINATED Phase PHASE2
NCT02619565 Prospective Study of Molecular Predictors of Survival in Myelodysplastic Syndromes Status COMPLETED Phase NA
NCT02619097 Safety & Pharmacokinetics of Pegolsihematide for Treatment of Anemia Patient With Myelodysplastic Syndromes Status UNKNOWN Phase PHASE1
NCT02610777 An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML) Status COMPLETED Phase PHASE2
NCT02598661 Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Status ACTIVE_NOT_RECRUITING Phase PHASE2/PHASE3
NCT02593123 Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis Status COMPLETED Phase PHASE2
NCT02576301 Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS Status UNKNOWN Phase PHASE1/PHASE2
NCT02564536 Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS) Status WITHDRAWN Phase PHASE1
NCT02508870 A Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes Status COMPLETED Phase PHASE1
NCT02498665 A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies Status COMPLETED Phase PHASE1
NCT02497404 Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR Status COMPLETED Phase PHASE2
NCT02493829 B7.1/IL-2 Leukaemia Cell Vaccine for Non-Transplant AML RFUSIN2-AML2 (NTX) Status UNKNOWN Phase PHASE1
NCT02489929 Evaluation of Cytidine Deaminase for Patient Suffering of a Myelodysplastic Syndrom or an AML Treated by Azacytidine Status UNKNOWN Phase NA
NCT02488408 A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS Status COMPLETED Phase PHASE1/PHASE2
NCT02477878 Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT02472691 Azacitidine, Lenalidomide and DLI as Salvage Therapy for MDS, CMML and sAML Relapsing After Allo-HSCT Status COMPLETED Phase PHASE2
NCT02452983 Sertraline in Treatment of Low-Risk Myelodysplastic Syndrome Status TERMINATED Phase PHASE1